Pages that link to "Q34145251"

The following pages link to Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data. (Q34145251):

Displaying 35 items.

• Lifetime antipsychotic medication and cognitive performance in schizophrenia at age 43 years in a general population birth cohort (Q30835228) (← links)
• The effect of COMT Val158Met and DRD2 C957T polymorphisms on executive function and the impact of early life stress (Q33695382) (← links)
• Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review (Q33878816) (← links)
• Association between Dopamine Receptor D2 (DRD2) Variations rs6277 and rs1800497 and Cognitive Performance According to Risk Type for Psychosis: A Nested Case Control Study in a Finnish Population Sample (Q35675412) (← links)
• Cognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: a 6-month, open-label, randomized, pilot trial. (Q36033253) (← links)
• Dopamine D2/3 Receptor Occupancy Following Dose Reduction Is Predictable With Minimal Plasma Antipsychotic Concentrations: An Open-Label Clinical Trial (Q36377903) (← links)
• Increased Nigral SLC6A3 Activity in Schizophrenia Patients: Findings From the Toronto-McLean Cohorts (Q36817270) (← links)
• Frontal D2/3 Receptor Availability in Schizophrenia Patients Before and After Their First Antipsychotic Treatment: Relation to Cognitive Functions and Psychopathology (Q36950595) (← links)
• Effects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: an open-label, randomized, controlled, pilot study (Q37131080) (← links)
• Use of translational pharmacodynamic biomarkers in early-phase clinical studies for schizophrenia. (Q38170140) (← links)
• Β-Amyloid Burden is Not Associated with Cognitive Impairment in Schizophrenia: A Systematic Review (Q38831113) (← links)
• A neuroimaging study of emotion-cognition interaction in schizophrenia: the effect of ziprasidone treatment (Q38955981) (← links)
• Do antipsychotics lead to cognitive impairment in dementia? A meta-analysis of randomised placebo-controlled trials (Q39485229) (← links)
• Lack of association between dopaminergic antagonism and negative symptoms in schizophrenia: a positron emission tomography dopamine D2/3 receptor occupancy study (Q41656833) (← links)
• Antipsychotic Use Pattern in Schizophrenia Outpatients: Correlates of Polypharmacy. (Q42707831) (← links)
• Sex differences in the relationship between prolactin levels and impaired processing speed in early psychosis (Q47566044) (← links)
• Cognition and Dopamine D2 Receptor Availability in the Striatum in Older Patients with Schizophrenia (Q47913720) (← links)
• Serum levels of second-generation antipsychotics are associated with cognitive function in psychotic disorders (Q47920400) (← links)
• Positive Allosteric Modulation of the Muscarinic M1 Receptor Improves Efficacy of Antipsychotics in Mouse Glutamatergic Deficit Models of Behavior (Q48354605) (← links)
• Hippocampal subregion volume changes associated with antipsychotic treatment in first-episode psychosis. (Q50895638) (← links)
• Determination of dopamine D₂ receptor occupancy by lurasidone using positron emission tomography in healthy male subjects. (Q51015027) (← links)
• Effects of Continuing Oral Risperidone vs. Switching from Risperidone to Risperidone Long-Acting Injection on Cognitive Function in Stable Schizophrenia Patients: A Pilot Study. (Q52641630) (← links)
• Effects of anticholinergic challenge on psychopathology and cognition in drug-free patients with schizophrenia and healthy volunteers. (Q52654822) (← links)
• The relationship between dopamine receptor blockade and cognitive performance in schizophrenia: a [11C]-raclopride PET study with aripiprazole. (Q53403706) (← links)
• Benefit of extending the dosing interval of long-acting antipsychotic injections in elderly schizophrenics with cognitive dysfunction. (Q54748022) (← links)
• Variations in Dysbindin-1 are associated with cognitive response to antipsychotic drug treatment. (Q55216457) (← links)
• Intrinsically regulated learning is modulated by synaptic dopamine signaling (Q57039916) (← links)
• Anticholinergic discontinuation and cognitive functions in patients with schizophrenia: a pharmacist–physician collaboration in the outpatient department (Q59126207) (← links)
• Dopamine modulates the reward experiences elicited by music (Q61067978) (← links)
• Factors associated with successful antipsychotic dose reduction in schizophrenia: a systematic review of prospective clinical trials and meta-analysis of randomized controlled trials (Q91466571) (← links)
• Nicotine consumption during the prodromal phase of schizophrenia - a review of the literature (Q91705551) (← links)
• Effects of olanzapine during cognitive and emotional processing in schizophrenia: A review of functional magnetic resonance imaging findings (Q92552137) (← links)
• Attenuation Effects of Alpha-Pinene Inhalation on Mice with Dizocilpine-Induced Psychiatric-Like Behaviour (Q92997044) (← links)
• Cognitive impairment in psychotic illness: prevalence, profile of impairment, developmental course, and treatment considerations (Q95586193) (← links)
• Subcortical Dopamine and Cognition in Schizophrenia: Looking Beyond Psychosis in Preclinical Models (Q97519770) (← links)